Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new coronavirus

Informazioni relative al progetto

Solnatide

ID dell’accordo di sovvenzione: 101003595

DOI

10.3030/101003595

Progetto chiuso

Data della firma CE 30 Marzo 2020

Data di avvio 1 Aprile 2020

Data di completamento 30 Giugno 2022

Finanziato da

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Costo totale

€ 1 626 025,00

Contributo UE

€ 1 626 025,00

Coordinato da

RTDS - VEREIN ZUR FORDERUNG DER KOMMUNIKATION UND VERMITTLUNG VON FORSCHUNG, TECHNOLOGIE UND INNOVATION (RTDS VEREIN, ENGL. RTDS ASSOCIATION)
Austria

CORDIS fornisce collegamenti ai risultati finali pubblici e alle pubblicazioni dei progetti ORIZZONTE.

I link ai risultati e alle pubblicazioni dei progetti del 7° PQ, così come i link ad alcuni tipi di risultati specifici come dataset e software, sono recuperati dinamicamente da .OpenAIRE .

Risultati finali

Documents, reports (3)

GMP (Good Manufacturing Practice) certificate

After completion of the manufacture, a GMP Compliance Certificate will be issued.

SOLANTIDE Draft Clinical Study Report of COVID-19 patients

The PI will prepare a draft clinical study report and all data exported in the eSystem to generate a first statistical draft summary

Report on the suitability of solnatide IMP for treatment of COVID-19

Clinical data related to experience of Solnatide in corona patients will be reported and published

Pubblicazioni

Peer reviewed articles (4)

Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate to severe ARDS in a randomized, placebo-controlled, double-blind trial: preliminary evaluation of safety and feasibility in light of the COVID- 19 pandemic

Autori: Schmid, Benedikt; Kranke, Peter; Lucas, Rudolf; Maybohm, Patrick; Zwissler, Bernhard; Frank, Susanne
Pubblicato in: Trials, Numero 2, 2022, ISSN 1745-6215
Editore: BioMed Central
DOI: 10.1186/s13063-022-06182-3

Conformational ensemble of the TNF-derived peptide solnatide in solution

Autori: Martin-Malpartida, Pau; Arrastia-Casado, Silvia; Farrera-Sinfreu, Josep; Lucas, Rudolf; Fischer, Hendrik; Fischer, Bernhard; Eaton, Douglas C.; Tzotzos, Susan; Marcias, Maria J.
Pubblicato in: Computational and Structural Biotechnology Journal, Numero 1, 2022, ISSN 2001-0370
Editore: Elsevier
DOI: 10.1016/j.csbj.2022.04.031

Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey.

Autori: Bernhard Fischer; Hendrik Fischer; Markus Zeitlinger; Susan Tzotzos
Pubblicato in: Critical Care, Vol 24, Iss 1, Pp 1-4 (2020), Numero 1, 2020, ISSN 1364-8535
Editore: Springer
DOI: 10.1186/s13054-020-03240-7

Safety and preliminary efficacy of sequential multiple ascending doses of solnatide to treat pulmonary permeability edema in patients with moderate-to-severe ARDS-a randomized, placebo-controlled, double-blind trial.

Autori: Benedikt Schmid; Markus Kredel; Roman Ullrich; Katharina Krenn; Rudolf Lucas; Klaus Markstaller; Bernhard Fischer; Peter Kranke; Patrick Meybohm; Bernhard Zwißler; Sandra Frank; and the Solnatide Collaborators Group
Pubblicato in: Trials, Numero 1, 2021, ISSN 1745-6215
Editore: BioMed Central
DOI: 10.1186/s13063-021-05588-9